MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
$13,720,000
EPS
$0.46
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
0
78,000
947,000
452,000
Research and development
20,431,000
19,463,000
14,689,000
13,802,000
General and administrative
8,724,000
7,114,000
8,197,000
7,716,000
Impairment of indefinite-lived intangible and long-lived assets
-
-
56,700,000
-
Total operating expenses
29,155,000
26,577,000
79,586,000
21,518,000
Operating loss
-29,155,000
-26,499,000
-78,639,000
-21,066,000
Interest income
1,103,000
1,026,000
1,268,000
1,548,000
Interest expense
852,000
-
-
-
(loss) gain on change in fair value of warrant liability
118,000
-94,000
-707,000
-516,000
Loss on change in fair value of embedded derivative
4,535,000
-
-
-
Gain on change in fair value of contingent value rights liability
-49,200,000
13,800,000
23,100,000
16,900,000
Loss on change in fair value of forward contract liabilities
-
-
0*
0
Other income (expense), net
126,000
-3,000
4,889,750*
0
Total other income, net
44,924,000
-12,683,000
-16,235,250
-
Loss before income taxes
-
-
-94,874,250*
-
Income tax benefit (expense)
-
-
-2,298,250*
-
Net income (loss)
15,769,000
-39,182,000
-92,576,000
-35,902,000
Foreign currency translation adjustment
-
-7,000
11,000
-10,000
Less undistributed earnings allocable to participating securities, basic
2,049,000
-
-
-
Total comprehensive loss
-
-39,189,000
-92,565,000
-35,912,000
Net income (loss) allocable to shares of common stock - basic
13,720,000
-
-
-
Basic EPS
0.47
-1.46
-3.559
-1.38
Diluted EPS
0.46
-1.46
-3.624
-1.38
Basic Average Shares
29,467,130
26,855,158
26,007,512
26,002,892
Diluted Average Shares
29,860,880
26,855,158
25,540,523
26,002,892
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Gain on change in fair
value of contingent...
-$49,200,000
(-39.38%↓ Y/Y)
Interest income
$1,103,000
(-36.90%↓ Y/Y)
Other income
(expense), net
$126,000
(2620.00%↑ Y/Y)
Total other income,
net
$44,924,000
Loss on change in fair
value of embedded...
$4,535,000
Interest expense
$852,000
(loss) gain on change in
fair value of warrant...
$118,000
(118.04%↑ Y/Y)
Net income (loss)
$15,769,000
(-0.74%↓ Y/Y)
Operating loss
-$29,155,000
(-33.67%↓ Y/Y)
Net income (loss)
allocable to shares of...
$13,720,000
Less undistributed
earnings allocable to...
$2,049,000
Total operating
expenses
$29,155,000
(31.87%↑ Y/Y)
Research and development
$20,431,000
(37.41%↑ Y/Y)
General and
administrative
$8,724,000
(20.50%↑ Y/Y)
Buy us a coffee
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)